Cogent Biosciences at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Cogent Biosciences brings 1 presentation to ASH 2026 in New Orleans, and exhibits at Booth 3812. Its program centres on systemic mastocytosis. It hosts a forum on recognizing the disease from patient and clinician views and supports a symposium on care decisions.
| Organization | ASH 2026 Attendance |
|---|---|
Cogent Biosciences Waltham, MA | |
Biotech developing precision therapies for genetically defined diseases; lead drug bezuclastinib, a mutant-KIT inhibitor, is in late-stage trials for systemic mastocytosis and GIST. | Booth Exhibiting at Booth 3812 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00pm–10:00pm Clinical Turning Points: Decisions That Shape Care Across the Spectrum of Systemic Mastocytosis Recognizing the full symptom burden of non-advanced systemic mastocytosis, judging disease control, and deciding when to escalate to disease-directed therapy. |
Find decision makers at Cogent Biosciences
Tell us what you sell and we’ll find the people at Cogent Biosciences most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction